Dr. Howard Liang was recognized by the Wall Street Journal's "Best on the Street" special report for stock picking in both biotechnology and pharmaceuticals in 2010, and in biotechnology in 2008. In addition, he was named the number-two stock picker for biotechnology in the 2011 Financial Times/StarMine Analyst Awards. Liang joined the Leerink Swann biotech team in 2005, having worked at A.G. Edwards, where he was a senior biotechnology analyst. Liang spent eight years at Abbott Laboratories, where he was a senior scientist and a member of one of the industry's leading structure-based drug discovery teams. Liang has authored papers in prestigious journals including Nature, Science, and Proceedings of the National Academy of Sciences. He obtained his Master's of Business Administrtation and Ph.D. in biochemistry and molecular biology, both from the University of Chicago. He has a Bachelors of Science degree in chemistry from Beijing University.